Abstract: Deuremidevir hydrobromide acts on the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 in the active form of nucleoside triphosphate and blocks viral RNA replication by binding to the active center of the RdRp catalytic subunit, thus playing an antiviral role. On January 28, 2023, after the emergency review and approval of the National Medical Products Administration (NMPA), the deuremidevir hydrobromide tablets were conditionally approved for the market, for the treatment of mild to moderate COVID-19 in adult patients. This article introduces the clinical research and development practice of deuremidevir hydrobromide tablets, aiming to provide ideas and reference for the research and development of urgently needed drugs in public health emergencies.